Oryzon Genomics S.A.
- Address
- Avinguda De Sant Ferran 74, Poligono Industrial Cornella De Llobregat
Sponsor Overview
Specializations
Schizophrenia and neuropsychiatric disorders
Oryzon Genomics S.A. is involved in clinical research on schizophrenia, with a focus on negative symptoms and cognitive impairment in adult patients.
- Negative symptom burden
- Cognitive dysfunction
- Adult psychiatric populations
The sponsor’s portfolio includes studies centered on neuropsychiatric symptom domains that affect daily functioning and clinical outcomes.
Hematology and myeloproliferative disease
Its research activity includes essential thrombocythemia, particularly in patients who are resistant or intolerant to prior therapy, with attention to abnormal platelet counts and disease control.
- Essential thrombocythemia
- Platelet count abnormalities
- Treatment-resistant disease
This area reflects an interest in myeloproliferative neoplasms and the management of persistent hematologic abnormalities in adults.
Sickle cell disease
The sponsor is also studying sickle cell disease, extending its hematology program into inherited red blood cell disorders with significant clinical burden.
- Sickle cell disease
- Inherited blood disorders
- Adult patient care
These studies place emphasis on disease areas where chronic hematologic dysfunction and complication risk are central therapeutic concerns.
Healthy volunteer pharmacology
Oryzon Genomics S.A. also supports research in healthy male participants to characterize absorption, distribution, metabolism, and excretion of an investigational compound.
- Healthy volunteers
- Pharmacokinetics
- Drug disposition
This work contributes to understanding how the sponsor’s compounds behave in the body alongside its disease-focused programs.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Iadademstat in the Management of Sickle Cell Disease in Affected Patients |  Spain | Recruiting |
| Evaluation of Vafidemstat on Negative Symptoms and Cognitive Impairment in Adult Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial |  Bulgaria Poland Romania Slovakia Spain | Recruiting |
| Phase 1 Open-Label Study of Absorption, Distribution, Metabolism, and Excretion of [14C]-Vafidemstat in Healthy Male Volunteers |  The Netherlands | Not Recruiting |
| Phase 2 Study of Iadademstat in Patients with Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea | Spain | Recruiting |
| Phase I, open-label, randomized crossover study assessing the pharmacokinetics and food effect of Iadademstat in healthy volunteers | Spain | Not Yet Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 2 are not being studied by other sponsors.
This sponsor has worked with 47 sites across their trial portfolio.
Therapeutic Focus
- 1.Hemic and Lymphatic Diseases2 trials249 other sponsors
- 2.Not possible to specify2 trials220 other sponsors
- 3.Mental Disorders1 trial150 other sponsors
Partnered Research Centres
47 centres- Address
- Avenida De Las Islas Baleares 3, 09006 Burgos
- Address
- Bulevard Tutrakan 20, 7003 Rousse
- Address
- CALLE ALEJANDRO CASONA (s/n), 33013 Oviedo
- Address
- Ul. Na Zaspe 3, 80-546 Gdansk
- Address
- Ul. 28 Czerwca 1956 R. 194, 61-485 Poznan
- Address
- Ul. Tarnopolska 77, 41-807 Zabrze
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Oryzon Genomics S.A..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.